Berlin, October 30, 2024 – YPOG advised global artificial intelligence (AI) company Aignostics on its latest $34 million Series B financing round. The round was led by ATHOS, with investments from the Mayo Clinic and growth financing from HTGF. It also received investments from existing investors including Wellington Partners, Boehringer Ingelheim Venture Fund, CARMA Fund, and the VC Fonds Technologie managed by IBB Ventures. Aignostics has raised more than $55 million to date, demonstrating investor confidence in its unique AI models and well-defined commercial strategy.
Started in 2018, Aignostics was initially founded as a spin-off from Charité and Berlin Institute of Health in 2020. The AI company turns complex multimodal pathology data into transformative insights.
Following the closing of the latest financing round, Aignostics plans to create new products for biopharmaceutical clients, drive growth in the United States, and develop advanced foundation models for pathology in collaboration with Mayo Clinic. The new funding will enhance Aignostics’ capabilities in target identification, translational research, and companion diagnostics (CDx), while also backing various strategic initiatives.
“2024 has been a pivotal year for us that has included a major strategic collaboration with Bayer and the launch of our first foundation model, RudolfV,” says Viktor Matyas, CEO and Co-Founder of Aignostics. “With RudolfV, we’ve gained the ability to quickly develop cost-efficient algorithms that generalize to the real-world. Now with this new round of funding, we’re turning our most popular algorithms into products that will help usher in an era of truly generalizable AI for computational pathology.”
Team
Dr. Martin Schaper (Lead, Corporate/Transactions), Partner, Berlin
Dr. Jonas von Kalben (Transactions), Senior Associate, Berlin
Anja Schindler (Transactions), Senior Associate, Berlin
Benedikt Kreuder (Transactions), Senior Associate, Berlin
Dr. Jacob Schreiber (Transactions), Senior Associate, München
About Aignostics
Aignostics is an artificial intelligence (AI) company that turns complex multimodal pathology data into transformative insights. By combining proprietary access to multimodal clinical data, industry-leading technologies, and rigorous science, Aignostics develops best-in-class products and services for the next generation of precision medicine. Through collaborations with its biopharma partners, Aignostics supports drug discovery, translational research, clinical trials, and CDx development. Established in 2018, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading investors and has operations in Berlin and New York.
Further information at aignostics.com
